Fri, September 23, 2022

Josh Schimmer Upgraded (SPRO) to Buy and Increased Target to $8 on, Sep 23rd, 2022

Josh Schimmer of Evercore ISI Group, Upgraded "Spero Therapeutics, Inc." (SPRO) to Buy and Increased Target from $2 to $8 on, Sep 23rd, 2022.

Josh has made no other calls on SPRO in the last 4 months.



There is 1 other peer that has a rating on SPRO. Out of the 1 peers that are also analyzing SPRO, 0 agree with Josh's Rating of Hold.



This is the rating of the analyst that currently disagrees with Josh


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Monday, August 15th, 2022